MedTrace Logo

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

NCT07043270 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-10-20

No results posted yet for this study

Summary

The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.

Conditions

  • Pancreas Adenocarcinoma

Interventions

DRUG

Nab-paclitaxel + Gemcitabine

Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).

DRUG

modified FOLFIRINOX (mFOLFIRINOX)

Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-29
Primary Completion
2028-07-01
Completion
2029-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07043270 on ClinicalTrials.gov